Literature DB >> 1361394

Regulatory role of brain angiotensins in the control of physiological and behavioral responses.

J W Wright1, J W Harding.   

Abstract

Considerable evidence now indicates that a separate and distinct renin-angiotensin system (RAS) is present within the brain. The necessary precursors and enzymes required for the formation and degradation of the biologically active forms of angiotensins have been identified in brain tissues as have angiotensin binding sites. Although this brain RAS appears to be regulated independently from the peripheral RAS, circulating angiotensins do exert a portion of their actions via stimulation of brain angiotensin receptors located in circumventricular organs. These circumventricular organs are located in the proximity of brain ventricles, are richly vascularized and possess a reduced blood-brain barrier thus permitting accessibility by peptides. In this way the brain RAS interacts with other neurotransmitter and neuromodulator systems and contributes to the regulation of blood pressure, body fluid homeostasis, cyclicity of reproductive hormones and sexual behavior, and perhaps plays a role in other functions such as memory acquisition and recall, sensory acuity including pain perception and exploratory behavior. An overactive brain RAS has been identified as one of the factors contributing to the pathogenesis and maintenance of hypertension in the spontaneously hypertensive rat (SHR) model of human essential hypertension. Oral treatment with angiotensin-converting enzyme inhibitors, which interfere with the formation of angiotensin II, prevents the development of hypertension in young SHR by acting, at least in part, upon the brain RAS. Delivery of converting enzyme inhibitors or specific angiotensin receptor antagonists into the brain significantly reduces blood pressure in adult SHR. Thus, if the SHR is an appropriate model of human essential hypertension (there is controversy concerning its usefulness), the potential contribution of the brain RAS to this dysfunction must be considered during the development of future antihypertensive compounds.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361394     DOI: 10.1016/0165-0173(92)90018-h

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  26 in total

1.  Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning.

Authors:  J W Wright; L Stubley; E S Pederson; E A Kramár; J M Hanesworth; J W Harding
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

Review 2.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

3.  Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.

Authors:  S Zini; M C Fournie-Zaluski; E Chauvel; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.

Authors:  Fabrice Balavoine; Michel Azizi; Damien Bergerot; Nadia De Mota; Rémi Patouret; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

5.  Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen.

Authors:  M Schinke; O Baltatu; M Böhm; J Peters; W Rascher; G Bricca; A Lippoldt; D Ganten; M Bader
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Cardiovascular effect of angiotensin-(1-12) in the caudal ventrolateral medullary depressor area of the rat.

Authors:  Tetsuya Kawabe; Kazumi Kawabe; Hreday N Sapru
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-27       Impact factor: 4.733

7.  Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.

Authors:  P Picard; L Chrétien; R Couture
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

8.  Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia/reperfusion injury: an experimental trial in rats.

Authors:  Maha Mohammed Abdel-Fattah; Basim Anwar Shehata Messiha; Ahmed Mohamed Mansour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-17       Impact factor: 3.000

Review 9.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

Review 10.  RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.

Authors:  Jay Lakkis; Wei X Lu; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.